Vol 73, No 1 (2022)
Original paper
Published online: 2022-01-31

open access

Page views 5873
Article views/downloads 505
Get Citation

Connect on Social Media

Connect on Social Media

Association of chemotactic cytokine receptor 5 (CCR5) gene polymorphism (59029 A/G, rs1799987) with diabetic kidney disease in patients with type 2 diabetes from Poland

Patrycja Pokrzywnicka1, Hanna Kwiendacz1, Katarzyna Nabrdalik1, Weronika Hajzler2, Piotr Adamczyk3, Dariusz Moczulski4, Wanda Trautsolt1, Władysław Grzeszczak†1, Janusz Gumprecht1
Pubmed: 35119091
Endokrynol Pol 2022;73(1):103-109.


Introduction: Diabetic kidney disease (DKD) pathogenesis is multifactorial and is a combination of metabolic, genetic, and environmental factors. Due to a long period of asymptomatic course, it is often diagnosed late when advanced stages of the disease are present. Among patients with diabetes, the presence of chemotactic cytokine receptor 5 (CCR5) gene polymorphism is suspected to be associated with the risk of DKD occurrence; however, the results of the research conducted so far are inconclusive. The aim of this study was to evaluate the CCR5 gene polymorphism (rs1799987, 59029 A/G) association with DKD among patients with type 2 diabetes mellitus (T2DM), who are residents of the Upper Silesia region of Poland.

Material and methods: CCR5 gene polymorphism (rs1799987, 59029 A/G) was assessed among consecutive patients with type 2 diabetes mellitus (T2DM) treated in a single outpatient diabetology clinic in Upper Silesia, Poland. Its association with DKD was examined. Additionally, selected clinical and demographic data were included in the analysis.

Results: Among 467 eligible study patients, there was no association between examined CCR5 gene polymorphism and the presence of DKD in relation both to the American Diabetes Association definition (p = 0.6) and to the National Kidney Foundation definition (p = 0.3) of this complication.

Conclusion: The presented study did not confirm the association between the examined gene polymorphism and the risk of DKD; further studies in this area are needed in order to establish or explicitly exclude this association.


Article available in PDF format

View PDF Download PDF file


  1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017; 12(12): 2032–2045.
  2. Persson F, Rossing P. Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl (2011). 2018; 8(1): 2–7.
  3. Matoba K, Takeda Y, Nagai Y, et al. Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease. Int J Mol Sci. 2019; 20(14).
  4. Zheng Z, Zheng F. Immune Cells and Inflammation in Diabetic Nephropathy. J Diabetes Res. 2016; 2016: 1841690.
  5. Tesch GH. Diabetic nephropathy - is this an immune disorder? Clin Sci (Lond). 2017; 131(16): 2183–2199.
  6. Cavalera M, Frangogiannis NG. Targeting the chemokines in cardiac repair. Curr Pharm Des. 2014; 20(12): 1971–1979.
  7. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004; 16(11): 1201–1210.
  8. Oo Z, Barrios CS, Castillo L, et al. High levels of CC-chemokine expression and downregulated levels of CCR5 during HIV-1/HTLV-1 and HIV-1/HTLV-2 coinfections. J Med Virol. 2015; 87(5): 790–797.
  9. Leach K, Charlton SJ, Strange PG. Analysis of second messenger pathways stimulated by different chemokines acting at the chemokine receptor CCR5. Biochem Pharmacol. 2007; 74(6): 881–890.
  10. Jin J, Colin P, Staropoli I, et al. Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry. J Biol Chem. 2014; 289(27): 19042–19052.
  11. Navratilova Z. Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006; 150(2): 191–204.
  12. Martinson JJ, Chapman NH, Rees DC, et al. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet. 1997; 16(1): 100–103.
  13. Blanpain C, Libert F, Vassart G, et al. CCR5 and HIV Infection. Recept Channels. 2011; 8(1): 19–31.
  14. Yang B, Houlberg K, Millward A, et al. Polymorphisms of chemokine and chemokine receptor genes in Type 1 diabetes mellitus and its complications. Cytokine. 2004; 26(3): 114–121.
  15. Mlynarski WM, Placha GP, Wolkow PP, et al. Risk of diabetic nephropathy in type 1 diabetes is associated with functional polymorphisms in RANTES receptor gene (CCR5): a sex-specific effect. Diabetes. 2005; 54(11): 3331–3335.
  16. Pettigrew KA, McKnight AJ, Patterson CC, et al. Resequencing of the CCL5 and CCR5 genes and investigation of variants for association with diabetic nephropathy. J Hum Genet. 2010; 55(4): 248–251.
  17. Nakajima K, Tanaka Y, Nomiyama T, et al. RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. Diabetes Care. 2003; 26(3): 892–898.
  18. Ahluwalia TS, Khullar M, Ahuja M, et al. Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One. 2009; 4(4): e5168.
  19. Buraczynska M, Zukowski P, Wacinski P, et al. Chemotactic cytokine receptor 5 gene polymorphism: relevance to microvascular complications in type 2 diabetes. Cytokine. 2012; 58(2): 213–217.
  20. Bagci B, Bagci G, Huzmeli C, et al. Associations of fractalkine receptor (CX3CR1) and CCR5 gene variants with hypertension, diabetes and atherosclerosis in chronic renal failure patients undergoing hemodialysis. Int Urol Nephrol. 2016; 48(7): 1163–1170.
  21. Yahya MJ, Ismail PB, Nordin NB, et al. Association of CCL2, CCR5, ELMO1, and IL8 Polymorphism with Diabetic Nephropathy in Malaysian Type 2 Diabetic Patients. Int J Chronic Dis. 2019; 2019: 2053015.
  22. Yadav AK, Kumar V, Dutta P, et al. Variations in CCR5, but not HFE, ELMO1, or SLC12A3, are associated with susceptibility to kidney disease in north Indian individuals with type 2 diabetes. J Diabetes. 2014; 6(6): 547–555.
  23. Mokubo A, Tanaka Y, Nakajima K, et al. Chemotactic cytokine receptor 5 (CCR5) gene promoter polymorphism (59029A/G) is associated with diabetic nephropathy in Japanese patients with type 2 diabetes: a 10-year longitudinal study. Diabetes Res Clin Pract. 2006; 73(1): 89–94.
  24. Kwiendacz H, Nabrdalik K, Adamczyk P, et al. Association of single nucleotide polymorphism (rs741301) of the ELMO1 gene with diabetic kidney disease in Polish patients with type 2 diabetes: a pilot study. Endokrynol Pol. 2020; 71(1): 66–72.
  25. Cunningham A, Benediktsson H, Muruve DA, et al. Trends in Biopsy-Based Diagnosis of Kidney Disease: A Population Study. Can J Kidney Health Dis. 2018; 5: 2054358118799690.
  26. Lorenzo-Medina M, De-La-Iglesia S, Ropero P, et al. Effect of hemoglobin Porto Alegre on glycated hemoglobin (HbA(1c)) measurement with the HA-8160 high performance liquid chromatography method. Clin Chem Lab Med. 2013; 51(10): e247–e249.
  27. Delanghe JR, Speeckaert MM. Creatinine determination according to Jaffe-what does it stand for? NDT Plus. 2011; 4(2): 83–86.
  28. Shahbaz H, Gupta M. Creatinine Clearance. StatPearls Publishing , Treasure Island 2021: StatPearls.
  29. McKnight AJ, Woodman AM, Parkkonen M, et al. Warren 3/UK GoKinD Study Group. Investigation of DNA polymorphisms in SMAD genes for genetic predisposition to diabetic nephropathy in patients with type 1 diabetes mellitus. Diabetologia. 2009; 52(5): 844–849.
  30. Prasad P, Tiwari AK, Kumar KM, et al. Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med Genet. 2007; 8: 20.
  31. Cao M, Tian Z, Zhang L, et al. Effects of 59029G/A polymorphism on the risk to diabetic nephropathy. Oncotarget. 2017; 8(63): 106926–106934.
  32. Tziastoudi M, Stefanidis I, Hadjigeorgiou GM, et al. A systematic review and meta-analysis of genetic association studies for the role of inflammation and the immune system in diabetic nephropathy. Clin Kidney J. 2017; 10(3): 293–300.
  33. Nazir N, Siddiqui K, Al-Qasim S, et al. Meta-analysis of diabetic nephropathy associated genetic variants in inflammation and angiogenesis involved in different biochemical pathways. BMC Med Genet. 2014; 15: 103.
  34. Zhang Z, Zhang X, Dong J, et al. Association of chemokine ligand 5/chemokine receptor 5 gene promoter polymorphisms with diabetic microvascular complications: A meta-analysis. J Diabetes Investig. 2016; 7(2): 212–218.
  35. Fuchsberger C, Flannick J, Teslovich TM, et al. The genetic architecture of type 2 diabetes. Nature. 2016; 536(7614): 41–47.
  36. Bhatnagar A. Environmental Determinants of Cardiovascular Disease. Circ Res. 2017; 121(2): 162–180.
  37. Marx N, Davies M, Grant P, et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2021; 9(1): 46–52.
  38. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018; 34(5): 575–584.
  39. Matosin N, Frank E, Engel M, et al. Negativity towards negative results: a discussion of the disconnect between scientific worth and scientific culture. Dis Model Mech. 2014; 7(2): 171–173.